MedTrace Logo

Determination of Amifostine Levels During Radiation Therapy

NCT00286611 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2008-06-10

No results posted yet for this study

Summary

Currently, there are no published methods for easily determining the level of amifostine in the blood or saliva. A method has been developed within the Department of Radiation Oncology by Drs. Douglas Spitz and Gurminder Sidhu, within the Spitz Lab. This method has been tested using both animal sampling and expired blood (obtained from DeGowin blood center) mixed with amifostine.

If the method proves successful, it could then be used as a tool to quantify blood and salivary amifostine levels and possibly correlate them to treatment efficacy or limiting adverse events using amifostine. A better method of treatment, either increasing the efficacy of amifostine or reducing its unwanted side effects, could then be developed.

Conditions

Interventions

PROCEDURE

Blood and salivary sampling of amifostine

Sampling of blood and saliva to test for amifostine levels.

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Principal Investigators

  • John M. Buatti, M.D. · University of Iowa Hospitals & Clinics

  • Douglas R. Spitz, Ph.D. · Carver College of Medicine University of Iowa

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00286611 on ClinicalTrials.gov